Literature DB >> 2261133

Sleep disturbances in HIV-infected homosexual men.

S E Norman1, A D Chediak, M Kiel, M A Cohn.   

Abstract

To provide a better understanding of the etiology of subjective sleep complaints in HIV-infected individuals, a study to evaluate sleep/wake disturbances in 10 healthy HIV-infected male volunteers was performed. All subjects were HIV-infected but had no history of AIDS-related infections, and considered clinically asymptomatic. Interviews and sleep questionnaires revealed sleep complaints in nine subjects. Five healthy HIV-seronegative male subjects, with no history of sleep complaints, were also evaluated. Sleep architecture analyses detected that, in comparison to published normative data and to negative controls, there was a significant increase in the total percentage of slow wave sleep (SWS) and an increase in the percentage of SWS in the later sleep cycles. When compared with normative data, an increase in stage 1 shifts, rapid eye movement (REM) periods, and arousals were also observed in the HIV-infected group. Significant decreases in sleep latency, total percentage stage 2 sleep, and average REM durations were also observed in the HIV-infected group compared with normative data. These sleep architecture abnormalities could not be attributed to known sole primary sleep disorders, first night effect, medications, anxiety or depression. This study indicates that sleep disturbances occur early in the course of HIV infection and suggests that the observed alterations of sleep physiology may be a consequence of central nervous system involvement and/or immune defense mobilization in the early phases of HIV infection.

Entities:  

Mesh:

Year:  1990        PMID: 2261133     DOI: 10.1097/00002030-199008000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Behavioral medicine interventions can improve the quality-of-life and health of persons with HIV disease.

Authors:  K J Sikkema; J A Kelly
Journal:  Ann Behav Med       Date:  1996-03

Review 2.  Sleep, immunity and inflammation in gastrointestinal disorders.

Authors:  Tauseef Ali; James Choe; Ahmed Awab; Theodore L Wagener; William C Orr
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Sleep and immunity: A growing field with clinical impact.

Authors:  Mark R Opp; James M Krueger
Journal:  Brain Behav Immun       Date:  2015-04-04       Impact factor: 7.217

4.  Sleep disturbances in persons living with HIV.

Authors:  Diana M Taibi
Journal:  J Assoc Nurses AIDS Care       Date:  2013 Jan-Feb       Impact factor: 1.354

5.  Insomnia symptoms and HIV infection among participants in the Women's Interagency HIV Study.

Authors:  Girardin Jean-Louis; Kathleen M Weber; Bradley E Aouizerat; Alexandra M Levine; Pauline M Maki; Chenglong Liu; Kathryn M Anastos; Joel Milam; Keri N Althoff; Tracey E Wilson
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

6.  Sleep quality and health-related quality of life in HIV-infected African-American women of childbearing age.

Authors:  Kenneth D Phillips; Richard L Sowell; Mary Boyd; Wesley D Dudgeon; Gregory A Hand
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

7.  Lifetime Methamphetamine Use Disorder and Reported Sleep Quality in Adults Living with HIV.

Authors:  Ni Sun-Suslow; Rowan Saloner; Vanessa Serrano; Anya Umlauf; Erin E Morgan; Ronald J Ellis; Scott Letendre; Igor Grant; Robert K Heaton
Journal:  AIDS Behav       Date:  2020-11

8.  Sleep patterns are disturbed in cats infected with feline immunodeficiency virus.

Authors:  O Prospéro-García; N Herold; T R Phillips; J H Elder; F E Bloom; S J Henriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 9.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

10.  Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3.

Authors:  Salvador Huitron-Resendiz; Sohela De Rozières; Manuel Sanchez-Alavez; Bernd Bühler; Ying-Chuan Lin; Danica L Lerner; Nicholas W Henriksen; Mboya Burudi; Howard S Fox; Bruce E Torbett; Steven Henriksen; John H Elder
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.